| Literature DB >> 26061170 |
Marije Swets1, Frank Van Dael2, Sabine Roza3, Robert Schoevers4, Inez Myin-Germeys2, Lieuwe de Haan5.
Abstract
The prevalence of obsessive-compulsive disorder in subjects with psychotic disorder is much higher than in the general population. The higher than chance co-occurrence has also been demonstrated at the level of subclinical expression of both phenotypes. Both extended phenotypes have been shown to cluster in families. However, little is known about the origins of their elevated co-occurrence. In the present study, evidence for a shared etiological mechanism was investigated in 3 samples with decreasing levels of familial psychosis liability: 987 patients, 973 of their unaffected siblings and 566 healthy controls. The association between the obsessive-compulsive phenotype and the psychosis phenotype c.q. psychosis liability was investigated. First, the association was assessed between (subclinical) obsessive-compulsive symptoms and psychosis liability. Second, in a cross-sib cross-trait analysis, it was examined whether (subclinical) obsessive-compulsive symptoms in the patient were associated with (subclinical) psychotic symptoms in the related unaffected sibling. Evidence was found for both associations, which is compatible with a partially shared etiological pathway underlying obsessive-compulsive and psychotic disorder. This is the first study that used a cross-sib cross-trait design in patients and unaffected siblings, thus circumventing confounding by disease-related factors present in clinical samples.Entities:
Mesh:
Year: 2015 PMID: 26061170 PMCID: PMC4465647 DOI: 10.1371/journal.pone.0125103
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Cross-sib cross-trait design.
Is one trait in one sib associated with another trait in the other sib?
Distribution of 2526 subjects in 1458 families.
| (patients + sibs) | Patients | Siblings | Controls | |
|---|---|---|---|---|
| 2526 (1458) | ||||
| Fam. with psychosis liability | 1960 (978) | 987 (934) | 973 (770) | - |
| Gen. Pop. controls | - | - | - | 566 (480) |
| Fam. with OCD pts. | 169 (83) | 91 (83) | 78 (65) | - |
| Fam. without OCD pts. | 1740 (851) | 896 (851) | 844 (661) | - |
| Fam.without pts. | 51 (44) | - | 51 (44) | - |
Notation: number of subjects in (number of families)
* families without patients with sufficient valid ybocs scores.
Descriptives of study population.
| Patients (n = 987) | Siblings (n = 973) | Controls (n = 566) | |
|---|---|---|---|
| Sex (% male) | 76.3 | 45.9 | 45.4 |
| Age (mean, sd) | 27.8 (8.2) | 27.8 (8.3) | 30.4 (10.6) |
|
| |||
| % < = primary | 12.7 | 7.8 | 2.8 |
| % secondary (VMBO/HAVO/MBO) | 59.8 | 51.8 | 43.1 |
| % higher (VWO/HBO/WO) | 25.2 | 38.4 | 53.4 |
|
| |||
| % married/living together | 9.1 | 49.9 | 39.8 |
| Ethnicity (% White) | 77.2 | 83.0 | 90.1 |
| Cannabis in urine (% positive) | 16.6 | 8.0 | 4.3 |
| IQ (mean, sd) | 95.0 (16.0) | 102.3 (15.5) | 109.7 (15.2) |
| Quality of life (% bad) | 14.9 | 3.6 | 1.6 |
|
| |||
| GAF(mean, sd) | 56 (15.9) | ||
|
| |||
| Schizophrenia | 659 (66,8%) | ||
| Schizophreniform disorder | 51(5,2%) | ||
| Other psychotic disorder | 156(15,8%) | ||
| Mood component (bipolar, schizoaffective, depressive) | 121 (15.8%) | ||
| Duration of illness (median, 95% range) | 3.6 (0.2–15.1) | ||
| Age at onset (mean, sd) | 22.3 (6.8) | ||
| Number of psychotic episodes (100% range) | 1–8 | ||
|
| |||
| No or unknown | 29.6 | ||
| Classic antipsychotics | 8.1 | ||
| Risperidon/quetiapine/aripiprazole | 28.6 | ||
| Clozapine | 7.7 | ||
| Olanzapine | 21.4 | ||
| Combinations | 4.5 |
Fig 2Prevalence of OCS in function of 3-level psychosis liability (status).
Clinical OCS: YBOCS>9. Broad OCS: YBOCS>0. * Differences in prevalence between distinct psychosis liability groups are all significant.
Associations between OCS and sibling status psychosis liability.
| Siblings vs. controls | ||
|---|---|---|
| SAMPLE | Level of expression of OC phenotype | OR (95% CI:), p |
| All families in whole sample | Broad OCS | |
| Adjusted for SIS-R pos. and neg. symptoms | 1.7 (1.0–2.6); p<0.03 | |
| Additionally adjusted for confounders * | 1.8 (1.1–2.9), p<0.02 | |
| Clinically relevant OCS | ||
| Adjusted for SIS-R pos. and neg. symptoms | 2.7 (1.3–5.9), p<0.01 | |
| Additionally adjusted for confounders * | 2.8 (1.3–6.2), p<0.01 | |
| Within fam. without OCD pts. | Broad OCS | |
| Unadjusted | 1.8 (1.1–2.8), p<0.01 | |
| Adjusted for SIS-R pos. and neg. symptoms | 1.6 (1.0–2.6), p<0.04 | |
| Additionally adjusted for confounders * | 1.7 (1.0–2.8), p<0.03 | |
| Clinically relevant OCS | ||
| Unadjusted | 2.5 (1.2–5.5). p<0.01 | |
| Adjusted for SIS-R pos. and neg. symptoms | 2.7 (1.3–5.9), p<0.01 | |
| Additionally adjusted for confounders * | 2.4 (1.1–5.5), p<0.03 | |
Controls = reference = 0; sibling of patient = 1
Associations are from multilevel logistic regression analysis, expressed in odds ratios; OR (95% CI:), p
Multilevel linear regression estimates with sibling SIS-R scores for positive psychotic experiences as dependent variable and patient dichotomous YBOCS scores (> = 16 vs. <16) as independent variable.
| Level of expression of OC phenotype | B (95% CI), p |
|---|---|
| Broad OCS | 0.5 (-0.02–0.95), p<0.06 |
| Adjusted demo (not age) | 0.5 (.02–1.0), p<.04 |
| Adjusted demo (incl. age) | 0.5 (-0.04–0.95), p<.07 |
| Adjusted demo + pharma | 0.4 (-0.1–0.9), p<0.2 |
| Clinically relevant OCS | 0.4 (-0.1–0.9), p<0.1 |
| Adjusted demo (not age) | 0.4 (-0.1–0.9), p<0.1 |
| Adjusted demo (incl. age) | 0.4 (-0.1–0.9), p<0.1 |
| Adjusted demo + pharma | 0.3 (-0.28–0.8), p<0.4 |
Associations from multilevel linear regression equations, expressed as B (95% CI), p
* Adjusted for confounders sex, level of education, IQ, marital status,
**Additionally adjusted for age
**Additionally adjusted for use of antidepressants, use of antipsychotics.